Vireo Growth (VREOD) versus Its Rivals Critical Contrast

Vireo Growth (OTCMKTS:VREOD) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Vireo Growth to related businesses based on the strength of its profitability, valuation, institutional ownership, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Vireo Growth and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vireo Growth	$268.77 million	-$68.11 million	-3.02
Vireo Growth Competitors	$3.54 billion	$3.18 billion	553.85

Vireo Growth’s peers have higher revenue and earnings than Vireo Growth. Vireo Growth is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Vireo Growth has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Vireo Growth’s peers have a beta of -3.71, meaning that their average stock price is 471% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vireo Growth and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vireo Growth	1	0	0	0	1.00
Vireo Growth Competitors	7798	13888	25778	1037	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.65%. Given Vireo Growth’s peers stronger consensus rating and higher possible upside, analysts plainly believe Vireo Growth has less favorable growth aspects than its peers.

Profitability

This table compares Vireo Growth and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vireo Growth	-23.37%	-19.76%	-7.15%
Vireo Growth Competitors	-2,380.38%	-217.94%	-15.54%

Institutional and Insider Ownership

32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.8% of Vireo Growth shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Vireo Growth peers beat Vireo Growth on 9 of the 13 factors compared.

About Vireo Growth

Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.